Highest-materiality recent filing
AIM ImmunoTech regains NYSE American listing compliance after equity deficiency resolved
Received NYSE American notice on June 12, 2026 that it resolved stockholders' equity deficiencies under Sections 1003(a)(i)-(iii).
AIM ImmunoTech prices $2.65 million registered direct offering and private placement
Company issued 2,554,119 registered shares and 771,503 unregistered shares at $0.5189 per share for gross proceeds of ~$2.65M.
AIM ImmunoTech prices $2.4M registered direct offering of 7.5M shares and warrants
Offering of 7,519,351 shares at $0.325 per share; gross proceeds ~$2.4M before expenses.
AIM ImmunoTech increases stockholder equity to $2.1M, extends note maturity to June 2027
Stockholder equity rose to ~$2.1M as of March 31, 2026, from a deficit of ~$9.8M at Dec 31, 2025 (+$11.9M).
Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.
AIM ImmunoTech closes warrant inducement, raises ~$3.6M gross
Holders exercised Existing Warrants for 7,451,920 shares at reduced price of $0.48 per share.
AIM ImmunoTech expects ~$4.2M gross from warrant inducement at $0.48/share; new warrants at $0.60
Existing warrants from May 2024, Sep 2024, Jul 2025 exercised at reduced exercise price of $0.48; gross proceeds ~$4.2M if fully exercised.
AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales
Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.
Positive interim Phase 2 data for Ampligen+Imfinzi in metastatic pancreatic cancer
18 patients enrolled in DURIPANC Phase 2; combination well-tolerated with only two grade 3 immune-related AEs.
AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer
No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.
AIM ImmunoTech gets second NYSE American noncompliance notice for negative $3.9M equity
NYSE American warned AIM on June 17, 2025 for failing minimum stockholders' equity: negative $3.9M as of March 31, 2025.
AIM ImmunoTech completes 1-for-100 reverse split; regains NYSE American listing compliance
Reverse stock split at 1-for-100 ratio effective June 12, 2025; new CUSIP 00901B303.
AIM ImmunoTech shareholders approve reverse stock split up to 1-for-100
Special meeting held April 30, 2025; proposal passed with 23,041,332 for, 19,942,903 against.
AIM ImmunoTech receives NYSE American delisting notice for low stock price; plans appeal
Received notice on April 4, 2025 from NYSE American of suspension and delisting under Section 1003(f)(v) due to low selling price.
Phase 1 safety data showed combination generally well-tolerated with no severe adverse events or dose-limiting toxicities.
Aim ImmunoTech plans combo study of Ampligen and FluMist for avian flu
Plans to file IND for trial combining Ampligen with AstraZeneca's FluMist to target avian influenza.
AIM ImmunoTech gets safety committee nod for Phase 2 of Ampligen + Imfinzi in pancreatic cancer
Safety committee approved Phase 2 based on Phase 1 data: no severe adverse events or dose-limiting toxicities.
AIM ImmunoTech receives NYSE American delisting notice for stockholders' equity deficit
Stockholders' deficit of $2.9M as of Sept 30, 2024; fails $4M and $6M equity thresholds.
AIM ImmunoTech adopts amended bylaws following Delaware Supreme Court ruling
Company adopted Restated and Amended Bylaws on July 31, 2024.
Delaware Supreme Court rules on AIM Immunotech bylaw challenge; election unchanged
Delaware Supreme Court affirmed in part, reversed Court of Chancery post-trial decision in Kellner v. AIM Immunotech.
AIM ImmunoTech raises $2.0M in registered direct offering and warrant placement
Issues 5,640,958 shares at $0.363/share for gross proceeds of ~$2.0M to a single institutional investor.
AIM ImmunoTech reports positive Phase 2 topline results for Ampligen in post-COVID fatigue
Primary endpoint (PROMIS Fatigue Score at week 13) not significant; Ampligen showed lower fatigue at multiple timepoints vs placebo.
AIM ImmunoTech rejects stockholder Kellner's director nominations as invalid
Board determined notice from Ted D. Kellner nominating himself, Todd Deutsch, and Robert L. Chioini fails to comply with company bylaws.
On February 26, 2025, AIM ImmunoTech Inc. (the "Company") issued a press release announcing the appointment of David I. Chemerow to its Board of Directors (the "Board"), effective February 24, 2025
On March 30, 2023, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing the appointment of Nancy Bryan to its Board of Directors (the “Board”), effective March 28, 2023
On March 1, 2022, the Company entered into a consulting agreement with Ellen Lintal, who will step down as the Company’s Chief Financial Officer on April 4, 2022.
On March 1, 2022, after review and approval by the Board of Directors, the Company entered into a consulting agreement with Foresite Advisors, LLC, a company wholly-owned by Robert Dickey IV, pursuant to which Mr. Dickey will serve as the Company’s new Chief Financial Officer effective April 4, 2022.
Max materiality 0.80 · Median 0.55 · Most common event other_material